National Institute of Arthritis and Musculoskeletal and Skin Diseases

SINTX Technologies Awarded Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

Retrieved on: 
Wednesday, October 11, 2023
Silicon, DRS, Thomas Jefferson University, Acquisition, 3D, University of Pennsylvania School of Veterinary Medicine, Development, Human musculoskeletal system, Bacterial adhesion in aquatic system, Osseointegration, Veterinary medicine, Skin condition, University, Drexel University, Spine, SALT, Principal, FDA, PEEK, Arthritis, Phase, Infection, Bangladesh Technical Education Board, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, SBIR, Pharmaceutical industry, Medical device, Research

This represents the fourth NIH grant awarded to SINTX since the Phase I award for this project was received in September of 2021.

Key Points: 
  • This represents the fourth NIH grant awarded to SINTX since the Phase I award for this project was received in September of 2021.
  • Through the development of 3DP SN-PEEK spinal implants, SINTX aims to combine the familiarity and benefits of PEEK with the antibacterial and osteoconductive characteristics of silicon nitride.
  • These composite implants will be manufactured with modern, cost-effective 3D printing technologies.
  • “Our successful completion of Phase I aims has shown the feasibility and reliability of 3DP SN-PEEK spinal implants.

INTERNATIONALLY RENOWNED DERMATOLOGIST AND PHYSICIAN SCIENTIST SHAWN KWATRA, MD, NAMED NEW CHAIR OF DERMATOLOGY AT THE UM SCHOOL OF MEDICINE AND CHIEF OF SERVICE OF DERMATOLOGY AT UM MEDICAL CENTER

Retrieved on: 
Monday, September 18, 2023
The New England Journal of Medicine, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Medical Affairs Bureau, Society, University of Maryland, College Park, Atopic dermatitis, Skin condition, Science, Maryland School, JAMA Dermatology, Hospital, Journal, Faculty, Prurigo nodularis, University, Physician, Service, Research, Paul Khavari, Johns Hopkins School of Medicine, Human musculoskeletal system, Knowledge, NIH, Skin, Duke University, Arthritis, Immunotherapy, FPI, University of Maryland School of Medicine, Diving Medical Advisory Council, MPH, University of Maryland Medical Center, Vinay Mohan Kwatra, UMMC, Wake Forest School of Medicine, Nature Medicine, UMMS, Joseph, Assistant professor, Pharmaceutical industry, Management, Medical device, Nursing, MD, Dermatology

Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.

Key Points: 
  • Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.
  • Dr. Kwatra joins UMSOM from Johns Hopkins University School of Medicine, where he served as the Founding Director of the Johns Hopkins Itch Center.
  • "It is an honor to be the next Chair of Dermatology at such a prestigious medical school," said Kwatra.
  • He earned his undergraduate degree from Duke University and his medical degree from Wake Forest University School of Medicine.

NDRI Receives $3.7 Million Grant from NIH to Continue the Development of NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program

Retrieved on: 
Wednesday, September 6, 2023
Science, Stem Cells, Other Science, Biotechnology, Research, Health, Hospitals, Genetics, NIDDK, Tissue, National Disease Research Interchange, Division of Program Coordination, Planning, and Strategic Initiatives, National Institute of Allergy and Infectious Diseases, Partnership, Arthritis, NEI, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Heart, Lung, and Blood Institute, Skin condition, Lung, Bangladesh Technical Education Board, MS, NHLBI, Kidney, NIAMS, National Eye Institute, National Institute of Diabetes and Digestive and Kidney Diseases, NDRI, Human musculoskeletal system, NIAID, Digestive, NIH, Infection, Pharmaceutical industry, Management

This new three-year award for NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program parent grant extends the NIH’s ongoing funding support for HTORR to 35 consecutive years.

Key Points: 
  • This new three-year award for NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program parent grant extends the NIH’s ongoing funding support for HTORR to 35 consecutive years.
  • The HTORR Program supports investigators across the full spectrum of research with access to normal and diseased human biospecimens.
  • “NDRI is grateful to the NIH for the support of our expanding HTORR program,” said Bill Leinweber, President and CEO of NDRI.
  • This grant renewal includes multiple enhancements such as a new Pilot Program, Pathology Service Options, and a Pathology Consultant Committee.

FesariusTherapeutics receives prestigious NIH SBIR research grant for DermiSphere™ hydrogel technology to treat full thickness skin loss

Retrieved on: 
Tuesday, August 8, 2023
Laboratory for Bioregenerative Medicine and Surgery, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Quality of life, Scar, Research, Skin condition, Bangladesh Technical Education Board, Pain, Regeneration, Patient, Division, Disease, Plastic, Weill Cornell Medicine, Burns, FDA, Trauma, Therapy, Laboratory, NIH, Skin, Pharmaceutical industry, Dentistry, MD, The Corbomite Maneuver

The rapid review and award of this major research grant will further accelerate the development of the company's suite of next generation product offerings.

Key Points: 
  • The rapid review and award of this major research grant will further accelerate the development of the company's suite of next generation product offerings.
  • The technology behind DermiSphere™ is designed to address the unmet need for effective and affordable treatment of full thickness skin loss, which can result from burns, trauma, surgery, or chronic wounds.
  • "We believe that DermiSphere™ has the potential to revolutionize the treatment of full thickness skin loss and improve the quality of life for millions of patients worldwide."
  • The research conducted is solely the responsibility of FesariusTherapeutics and does not necessarily represent the official views of the National Institutes of Health."

Lutris Pharma Presents Data From a Real-World Analysis of Skin Toxicity From EGFR Inhibitors - an Unmet Challenge, at the 2023 American Academy of Dermatology Annual Meeting

Retrieved on: 
Friday, March 17, 2023
Database, Arthritis, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Trinity, IQVIA, Xeroderma, Telangiectasia, Department of Medicine – University of Pamplona, Clinical trial, Medicine, State university system, Cancer, American Academy, Toxicity, Skin condition, Paronychia, Bangladesh Technical Education Board, TEL, Trichomegaly, State University of New York Upstate Medical University, Patient, AAD, EGFR, American Academy of Dermatology, Hyperpigmentation, Human musculoskeletal system, Poster, FDA, Rash, NIH, Skin, Pharmaceutical industry, Lutris

The analysis was supported, in part, by Lutris Pharma and the intramural research program of the National Institutes of Health (NIH).

Key Points: 
  • The analysis was supported, in part, by Lutris Pharma and the intramural research program of the National Institutes of Health (NIH).
  • While such patients are commonly treated prophylactically with antibiotics, there is insufficient evidence to support its practice, leading to a significant unmet medical need."
  • EGFR inhibitors are approved for the treatment of multiple epithelial tumors and can be either biologics or small molecules.
  • The poster will be available after the event on the "Events and Presentations" section of Lutris' website at: https://www.lutris-pharma.com/events-and-presentations/

Lutris Pharma Presents Data From a Real-World Analysis of Skin Toxicity From EGFR Inhibitors - an Unmet Challenge, at the 2023 American Academy of Dermatology Annual Meeting

Retrieved on: 
Friday, March 17, 2023
Database, Arthritis, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Trinity, IQVIA, Xeroderma, Telangiectasia, Department of Medicine – University of Pamplona, Clinical trial, Medicine, State university system, Cancer, American Academy, Toxicity, Skin condition, Paronychia, Bangladesh Technical Education Board, TEL, Trichomegaly, State University of New York Upstate Medical University, Patient, AAD, EGFR, American Academy of Dermatology, Hyperpigmentation, Human musculoskeletal system, Poster, FDA, Rash, NIH, Skin, Pharmaceutical industry, Lutris

The analysis was supported, in part, by Lutris Pharma and the intramural research program of the National Institutes of Health (NIH).

Key Points: 
  • The analysis was supported, in part, by Lutris Pharma and the intramural research program of the National Institutes of Health (NIH).
  • While such patients are commonly treated prophylactically with antibiotics, there is insufficient evidence to support its practice, leading to a significant unmet medical need."
  • EGFR inhibitors are approved for the treatment of multiple epithelial tumors and can be either biologics or small molecules.
  • The poster will be available after the event on the "Events and Presentations" section of Lutris' website at: https://www.lutris-pharma.com/events-and-presentations/

ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (NR) Supplementation

Retrieved on: 
Tuesday, January 25, 2022
Biotechnology, Health, Fitness & Nutrition, Pharmaceutical, Clinical Trials, Lupus, Skin condition, Patent, Securities Act of 1933, National Heart, Lung, and Blood Institute, Degenerative disease, NR, National, Research, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Patient, Laboratory, SLE, Annual report, ChromaDex, Monocyte, Senior, Human musculoskeletal system, National Institute, Metabolism, Publication, SEC, Systemic, NAD, Risk, Program, An Act to exempt a particular class of securities from the Securities and Exchange Act, NASDAQ, Clinical trial, Bureau of Oceans and International Environmental and Scientific Affairs, Journal, Company, Arthritis, NIH, NIH Intramural Research Program, Lung, Inflammation, Health, MRC Mitochondrial Biology Unit, BMI, Security (finance), Ageing, IFN, Pharmaceutical industry

ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen (patented nicotinamide riboside, or NR) ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation .

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen (patented nicotinamide riboside, or NR) ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation .
  • The study was conducted as part of the ChromaDex External Research Program (CERP) and adds to a growing body of clinical evidence supporting the potential anti-inflammatory effects of NR supplementation.
  • The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.
  • ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen.

Joshua Jacobs Named Board Chair at JBJS Inc.

Retrieved on: 
Thursday, January 27, 2022
Skin condition, Official Journal, Advisory council of Egypt's scientists and experts, William H. Harris (orthopaedic surgeon), National, AOA, Research, Rush Medical College, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Director, Book, Patient, The Journal of Bone and Joint Surgery, Board of directors, Trustee, Rush University Medical Center, Orthopedic surgery, National Institute, American Academy of Orthopaedic Surgeons, Human musculoskeletal system, Department, Twitter, Publication, Board, Inc., Orthopaedic Research Society, Arthritis, Journal, American Academy, CME, The Journal, MD, Advisory Council, Leadership, Dentistry, Pharmaceutical industry, JBJS

NEEDHAM, Mass., Jan. 27, 2022 /PRNewswire-PRWeb/ --Joshua J. Jacobs, MD has been named Chair of the Board of Trustees at The Journal of Bone and Joint Surgery (JBJS), Inc. An orthopaedic surgeon specializing in total joint replacement, Dr. Jacobs is currently Professor and Chair of the Department of Orthopaedic Surgery and Vice Dean for Research at Rush Medical College in Chicago.

Key Points: 
  • NEEDHAM, Mass., Jan. 27, 2022 /PRNewswire-PRWeb/ --Joshua J. Jacobs, MD has been named Chair of the Board of Trustees at The Journal of Bone and Joint Surgery (JBJS), Inc. An orthopaedic surgeon specializing in total joint replacement, Dr. Jacobs is currently Professor and Chair of the Department of Orthopaedic Surgery and Vice Dean for Research at Rush Medical College in Chicago.
  • "Josh's wide and deep experience guiding the boards of other top orthopaedic organizationscombined with his demonstrated leadership as a clinician, educator, and researchermakes him the ideal board Chair for JBJS," said Paul Sandford, JBJS, Inc. Chief Executive Officer.
  • Dr. Jacobs' term as Chair of the JBJS, Inc. Board of Trustees began on January 1, 2022 and will extend until December 31, 2023.
  • Other JBJS, Inc. publications include JBJS Case Connector, JBJS Essential Surgical Techniques, JBJS Reviews, Journal of Orthopaedics for Physician Assistants, and JBJS Open Access.

NIH Awards Imbed Biosciences $800K SBIR Grant to Kill Bacteria in Biofilms

Retrieved on: 
Thursday, October 14, 2021
Research, Medical Devices, Infectious Diseases, Contracts, Biotechnology, Health, General Health, Other Science, Science, Biofilm, IMB Bank, List of life sciences, Amputation, National Institute, Architecture, Principal investigator, Infection, CRP, Septic shock, Wound healing, Skin condition, School, National Institute of Arthritis and Musculoskeletal and Skin Diseases, FDA, Multimedia, Small Business Innovation Research, Veterinary medicine, National, Narayana Multispeciality Hospital, Mysore, SBIR, Critical care, Ion, Silver, University, Bacteria, Burns, CEO, NIH, Matrix, NIAMS, MD, List of Christian mission hospitals, Research, Surgery, Human musculoskeletal system, Pharmaceutical industry, Antibiotics

View the full release here: https://www.businesswire.com/news/home/20211014005922/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211014005922/en/
    Microlyte(R) Matrix and Microlyte(R) SURGICAL are available in a variety of sizes and are able to kill the bacteria associated with chronic wounds and surgical site infections.
  • Both products have been associated clinically with improved healing outcomes in a variety of acute, chronic, and traumatic wounds.
  • (Photo: Business Wire)
    Biofilms are colonies of bacteria on a surface that are insensitive to systemic antibiotics and topical antimicrobials.
  • The microscale architecture of Microlyte Matrix, which intimately conforms to a wound surface, will facilitate the synergistic action of the two metal ions to penetrate biofilms and kill multispecies bacteria hidden inside.

Octo Wins Contract to Support National Institute of Arthritis and Musculoskeletal and Skin Diseases

Retrieved on: 
Tuesday, August 31, 2021
White House, Federal Government, Public Policy, Government, Health, Technology, Other Technology, Other Health, Cloud, General manager, Structure of the Canadian federal government, NIAMS, Quality of life, Federation, PMO, Alaska Federal Health Care Access Network, Arthritis, Health, Project management office, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Intelligence, Public health, IT service management, Skin condition, National, Federal, NIH, Skin, Data science, Artificial intelligence, National Institute, Technology, Agile, Human musculoskeletal system, Cryptocurrency

Octo , the premier pure-play IT modernization provider for the Federal Government, announced today that it has won a $15 million contract to provide an IT Support Team for Task Order/Project Management (PM), Service Desk, Infrastructure Operations, and Project Management Office (PMO) support to National Institutes of Healths (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

Key Points: 
  • Octo , the premier pure-play IT modernization provider for the Federal Government, announced today that it has won a $15 million contract to provide an IT Support Team for Task Order/Project Management (PM), Service Desk, Infrastructure Operations, and Project Management Office (PMO) support to National Institutes of Healths (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
  • Octos Information Technology Services Support (ITSS) will include administering and maintaining associated hardware and implementing innovative software solutions for NIAMS.
  • We are honored to support NIAMS in bettering quality of life for those with arthritis, musculoskeletal, and skin diseases and finding ways to diagnose, treat and prevent those diseases through cutting-edge research, said Charlie McQuillan, General Manager of Federal Health for Octo.
  • Octo is a technology firm dedicated to solving the Federal Governments most complex challenges, enabling agencies to jump the technology curve.